INKT MiNK Therapeutics, Inc Company Short-Term Debt

MiNK Therapeutics - graphic logo of issuer INKT

MiNK Therapeutics, Inc. (INKT) short-term loan capital volume demonstrates liquidity dynamics, where the 0.00 level indicates the parameter's status. The issuer is developing an allogeneic platform, leveraging the hybrid properties of iNKT cells to combat cancer. High authority in oncology guarantees support from specialized funds. The monetization of ideas relies on partnerships with pharma behemoths and insurance reimbursements for therapy.

INKT minktherapeutics.com Short-Term Debt (07/04/2022 - 11/01/2026)

Analytical breakdowns and data insights for company MiNK Therapeutics, Inc (INKT)

- current quotes and average value forecast:
Price Chart MiNK Therapeutics|INKT - Average Forecast Price
- market capitalization data:
Market Value MiNK Therapeutics, Inc.|INKT - Total Company Value
- shareholders' equity book value data:
Net Assets per Single Share MiNK Therapeutics|INKT - Total Stockholders' Equity|Market Capitalization to Book Value Ratio minktherapeutics.com|INKT - Company Balance Sheet Assets
- company total debt and liquidity indicators:
Total Debt to Equity Ratio MiNK Therapeutics, Inc.|INKT - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio MiNK Therapeutics, Inc.|INKT - Aggregate Debt Obligations|Debts to Book Capitalization MiNK Therapeutics, Inc.|INKT - Long-Term Debt Volume|Company Short-Term Debt MiNK Therapeutics|Quick Liquidity minktherapeutics.com
- earnings and multiples data:
INKT - Net Income
General company analysis:MiNK Therapeutics (INKT)
Flagship merchandise of minktherapeutics.com

The stable management of MiNK Therapeutics, Inc. (INKT), which focuses on cancer immunotherapy, ensures transparency in liability management, as reflected in the book value of short-term debt. This indicator aggregates all accounts payable with maturities of up to one year, allowing investors to assess liquidity and the risk of capital shortages when servicing current loans amid volatile interest rates.

Competitors of MiNK Therapeutics, Inc.

IBRX - Company Short-Term Debt|Short-Term Debt Immunocore Holdings|Janux Pharma (JANX) - Company Short-Term Debt|RCUS (Arcus Corp) - Company Short-Term Debt|Company Short-Term Debt Zymeworks Inc.|Short-Term Debt tangotx.com TNGX|Company Short-Term Debts IOVA|Immatics NV (IMTX) - Short-Term Indebtedness|Xencor Corp - Company Current Liabilities|Compass Therapeutics Corp (CMPX) - Short-Term Debt|REPL: Company Current Liabilities|Company Short-Term Loans and Borrowings LYEL (lyell.com)|IPHA: Company Short-Term Debts|PYXS - Short-Term Debt Volume|Company Short-Term Debt Compugen Ltd|Company Current Liabilities IO Biotech Inc. (IOBT)|Company Short-Term Debt Sutro Biopharma, Inc. (STRO)|Company Current Liabilities werewolftx.com HOWL|Immix Biopharma - Company Current Liabilities|Company Short-Term Debts alxoncology.com ALXO|CUE - Company Short-Term Debt|PDSB (PDS Biotechnology) - Company Short-Term Indebtedness|sonnetbio.com (SONN) - Company Short-Term Debt|Short-Term Debt MAIABiotech.com (MAIA)|Company Current Liabilities LIMN|LVTX - Short-Term Indebtedness|Company Current Liabilities NXTC (NextCure Corp)|Amount of Current Liabilities LPTX|Company Short-Term Debts INTS (Intensity Therapeutics, Inc.)|Company Short-Term Loans and Borrowings SNSE|Theriva Biologics - Company Short-Term Debts|Short-Term Debt Gritstone bio, Inc.|Kineta Bio (KA) - Company Short-Term Debt|NexImmune Corporation - Company Short-Term Loans and Borrowings|TSBX (Turnstone Biologics Corp) - Company Short-Term Debts|Company Short-Term Debts vaccinex.com|Company Short-Term Debt Harpoon Therapeutics, Inc. (HARP)